Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

JAM(A), a chromosome 1q adhesion protein, is overexpressed in 1q amplified myeloma and may represent a novel therapeutic target for high-risk disease.

Niamh McCauley, Lara Donnelly, Roisin McAvera et al. Nov 03, 2025 pp. 5079-5079 10.1182/blood-2025-5079

Abstract Background: Gain(1q) is among the most frequent high-risk cytogenetic abnormalities in multiple myeloma (MM), closely linked with t...

Early loss of platelet response and rehospitalization following high-dose dexamethasone in patients with newly diagnosed ITP

Shira Buchrits, Gal Trieman, Danielle Fredman et al. Nov 03, 2025 pp. 1272-1272 10.1182/blood-2025-1272

Abstract Background: High-dose dexamethasone (HD-DXM) and prednisone are both standard first-line treatments for newly diagnosed immune thro...

Comparing CHOP, R-CHOP, R-EPOCH, and DA-EPOCH-R in HIV-associated diffuse large B-cell lymphoma: A meta-analysis and systematic review

Kai Wang, Michael Widjaja, Yue Faat Raymond Kwok Nov 03, 2025 pp. 5469-5469 10.1182/blood-2025-5469

Abstract INTRODUCTION Diffuse Large B-Cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma in patients with human immuno...

Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

Zhuo Wan, Yueru Ji, Dian Lou et al. Nov 03, 2025 pp. 1569-1569 10.1182/blood-2025-1569

Abstract Background: Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is associated with poor outcomes, with low compl...

Cardiovascular outcomes in CLL patients receiving GLP-1 agonists and  BTK inhibitors: A global propensity-matched study

Angimar Uriepero, Jose Milano, Elio Rodriguez et al. Nov 03, 2025 pp. 2774-2774 10.1182/blood-2025-2774

Abstract INTRODUCTION: Bruton tyrosine kinase inhibitors (BTKis) are becoming the preferred treatment for patients with chronic lymphocytic...

Srsf2P95H and Nf1 deficiency synergistically activate JAK-STAT signaling and exacerbate age-related clonal hematopoiesis in mice

Wangqing Dun, Yapu Li, Chaofan Geng et al. Nov 03, 2025 pp. 1388-1388 10.1182/blood-2025-1388

Abstract Clonal hematopoiesis (CH) is an age-related condition characterized by clonal expansion of hematopoietic stem cells (HSCs) bearing...

Chromameter-measured skin lightness: A novel noninvasive marker for liver iron in thalassemia patients

Phimpraphan Khumngeon, Sasinee Hantrakool, Napatra Tovanabutra et al. Nov 03, 2025 pp. 1137-1137 10.1182/blood-2025-1137

Abstract Introduction: Liver iron concentration (LIC), measured by magnetic resonance imaging (MRI), remains the gold standard for assessing...

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell et al. Nov 03, 2025 pp. 2707-2707 10.1182/blood-2025-2707

Abstract Introduction Treatment with anti-CD19 CAR T cell therapy for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (L...

Real world evidence of treatment patterns in hereditary hemorrhagic telangiectasia

Kristy Pahl, Heidi Cho, Alejandro Parralejo et al. Nov 03, 2025 pp. 6241-6241 10.1182/blood-2025-6241

Abstract Hereditary hemorrhagic telangiectasia (HHT), is an inherited bleeding disorder characterized by recurrent epistaxis, mucocutaneous...

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US

Idoroenyi Amanam, Chidera Agu, Siddhi Korgaonkar et al. Nov 03, 2025 pp. 4620-4620 10.1182/blood-2025-4620

Abstract Background: More than 80% of patients with LR-MDS have anemia, which is associated with a higher risk of cardia...

Singe agent off-the-shelf CAR-NK (CD-19 t-haNK) cell therapy in combination with rituxumab Results in complete response in participants with waldenstrom's macroglobulinemia

Jacqueline Thomson, David Brittain, Jacques Malherbe et al. Nov 03, 2025 pp. 5950-5950 10.1182/blood-2025-5950

Abstract Background: Relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), including incurable Waldenström's macroglobulinemia (WM...

Spectrum, molecular features, and clinical outcomes of hematologic malignancies and clonal hematopoiesis in li fraumeni syndrome

Elise Fiala, Kelsey Breen, Jennifer Kennedy et al. Nov 03, 2025 pp. 3220-3220 10.1182/blood-2025-3220

Abstract Background: Li Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by germline pathogenic varian...

Mitoxantrone liposome plus cytarabine and azacitidine for newly diagnosed Acute Myeloid Leukemia: A prospective, multicenter, randomized controlled study

Qianqian Yu, Xiaoyan Lv, WenJun Fang et al. Nov 03, 2025 pp. 5235-5235 10.1182/blood-2025-5235

Abstract Abstract introductionAcute myeloid leukemia (AML) is a genetically diverse type of blood cancer, making up around 70% of all acute...

Real-world discontinuation of cBTKi-based treatments in patients with CLL/SLL in the United States

Bita Fakhri, Katherine Winfree, Naleen Raj Bhandari et al. Nov 03, 2025 pp. 8030-8030 10.1182/blood-2025-8030

Abstract Background With the evolution of the treatment (tx) landscape, covalent Bruton tyrosine kinase inhibitors (cBTKi) are one of the mo...

Association between pre-existing mental health history and higher risk of mental health outcomes post-CAR-t therapy in patients with hematologic malignancies

Heidi Cho, Loren Caldwell, Alex Hughes et al. Nov 03, 2025 pp. 6271-6271 10.1182/blood-2025-6271

Abstract Background: Chimeric Antigen Receptor T-cell Therapy (CAR-T) has emerged as a revolutionary immunotherapy that utilizes genetically...

Identification of a development-restricted, megakaryocyte-primed population of hematopoietic progenitor cells during fetal and early postnatal development

Ryan Mack, Rohit Thalla, Lei Zhang et al. Nov 03, 2025 pp. 4936-4936 10.1182/blood-2025-4936

Abstract During development, hematopoiesis unfolds in successive, partially overlapping waves. Primitive and pre-definitive progenitors aris...

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Moshe Levy, David Andorsky, CelesteAnn Bremer et al. Nov 03, 2025 pp. 3775-3775 10.1182/blood-2025-3775

Abstract Introduction ASC, a BCR::ABL1 inhibitor that inhibits kinase activity by specifically targeting the ABL myristoyl pocket, has previo...

Immune recovery and immunologic remodeling after CD19-directed chimeric antigen receptor T cell therapy in autoimmune diseases

Andreas Riedel, Ann-Christin Pecher, Lucca Kimmich et al. Nov 03, 2025 pp. 2335-2335 10.1182/blood-2025-2335

Abstract Introduction Anti-CD19 Chimeric Antigen Receptor T cell therapy (CART19) is a promising treatment option for re...

Anti-leukemic efficacy of a novel inhibitor for KMT2A-r/FLT3-driven AML via multi-kinase targeting and synergy with menin inhibition

Nikola Niederlova, Pavla Koralkova, Pavla Chaloupkova et al. Nov 03, 2025 pp. 5059-5059 10.1182/blood-2025-5059

Abstract Introduction: Novel tyrosine kinase inhibitors (TKIs) are needed for combination therapy with menin inhibitors (menin-i) for KMT2A-...

Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL)

Neil Palmisiano, Juwhei Lee, David Claxton et al. Nov 03, 2025 pp. 1577-1577 10.1182/blood-2025-1577

Abstract Background: Relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) rem...

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

Michal Masar, Prokop Vodička, Samuel Hricko et al. Nov 03, 2025 pp. 3676-3676 10.1182/blood-2025-3676

Abstract Introduction Despite therapeutic advances, a significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) experienc...

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies

Andrés José María Ferreri, Teresa Calimeri, Urban Novak et al. Nov 03, 2025 pp. 1908-1908 10.1182/blood-2025-1908

Abstract Background: Primary central nervous system lymphomas (PCNSL) are rare, aggressive B-cell malignancies with distinct biological and...

Disparities in access to CAR-T therapy in a Medicaid-predominant population: A Louisiana case study highlighting policy lag

Dhara Popat, Prerana Ramesh, Brianna N Rogers et al. Nov 03, 2025 pp. 6318-6318 10.1182/blood-2025-6318

Abstract Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment for select hematologic malignancies. De...

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Anna Torrent, Mireia Morgades, Susana Barrera et al. Nov 03, 2025 pp. 5121-5121 10.1182/blood-2025-5121

Abstract Introduction. Adults with Ph-negative acute lymphoblastic leukemia (Ph- ALL) may not require allogeneic hematopoietic stem cell tra...

A non-canonical glycolytic endpoint supports HSC survival and function

Edward Owusu Kwarteng, Yafeng Li, Michalis Agathocleous Nov 03, 2025 pp. 858-858 10.1182/blood-2025-858

Abstract Glucose, the most abundant in vivo circulating nutrient, is essential for cell survival. Biochemistry textbooks posit glucose catab...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page